Literature DB >> 11061493

Augmentation of central arterial pressure in mild primary hyperparathyroidism.

J C Smith1, M D Page, R John, M H Wheeler, J R Cockcroft, M F Scanlon, J S Davies.   

Abstract

Primary hyperparathyroidism (PHPT) is associated with increased cardiovascular risk, although the mechanisms involved remain unclear. Recent evidence has shown increased pulse pressure to be a powerful predictor of cardiovascular events. As increases in pulse pressure are due largely to arterial stiffening, we measured arterial stiffness in 21 subjects with PHPT (18 women and 3 men; 46-71 yr old) and 21 age- and sex-matched healthy controls using pulse wave analysis, a technique that measures peripheral arterial pressure waveforms and generates corresponding central aortic waveforms. This allows determination of the augmentation of central pressure resulting from wave reflection and augmentation index, a measure of vessel stiffness. Metabolic parameters were also measured. The serum calcium level among PHPT subjects was (mean +/- SD) 2.74+/-0.14 mmol/L. pulse wave analysis showed that both augmentation and the augmentation index were significantly higher in the PHPT group vs. controls [16+/-5 vs. 10+/-4 mm Hg (P < 0.001) and 36+/-9% vs. 25+/-6% (P < 0.001)] despite comparable brachial systolic pressures between groups (136+/-13 vs. 134+/-18 mm Hg). Patients with PHPT had higher fasting serum insulin levels [median (range), 15.8 (7.4-39.4) vs. 11.6 (5.1-23) mU/L; P < 0.05] and triglyceride (1.6+/-0.6 vs. 1.2+/-0.4 mmol/L; P < 0.05), but lower high density lipoprotein cholesterol (1.4+/-0.4 vs. 1.6+/-0.3 mmol/L; P < 0.05). These data indicate that subjects with mild PHPT (calcium, <3.0 mmol/L) have increased arterial stiffness, as evidenced by higher augmentation of central aortic pressures. Enhanced vessel stiffness may arise from a combination of structural and functional vascular changes due to hypercalcemia and/or metabolic abnormalities. Increased vascular stiffness in subjects with PHPT may account in part for the increased cardiovascular risk in this group.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061493     DOI: 10.1210/jcem.85.10.6880

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  34 in total

1.  Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism.

Authors:  M D Walker; T Rundek; S Homma; M DiTullio; S Iwata; J A Lee; J Choi; R Liu; C Zhang; D J McMahon; R L Sacco; S J Silverberg
Journal:  Eur J Endocrinol       Date:  2012-06-01       Impact factor: 6.664

Review 2.  Mild primary hyperparathyroidism: a literature review.

Authors:  Megan K Applewhite; David F Schneider
Journal:  Oncologist       Date:  2014-07-25

3.  Increased arterial augmentation and augmentation index as surrogate parameters for arteriosclerosis in subjects with diabetes mellitus and nondiabetic subjects with cardiovascular disease.

Authors:  Birgit Wilhelm; Johannes Klein; Christiane Friedrich; Senait Forst; Andreas Pfützner; Peter H Kann; Matthias M Weber; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2007-03

4.  Elevation of parathyroid hormone levels in atrial fibrillation.

Authors:  Michiel Rienstra; Steven A Lubitz; Michael L Zhang; Rebecca R Cooper; Patrick T Ellinor
Journal:  J Am Coll Cardiol       Date:  2011-06-21       Impact factor: 24.094

5.  The evaluation and treatment of endocrine forms of hypertension.

Authors:  Alejandro Velasco; Wanpen Vongpatanasin
Journal:  Curr Cardiol Rep       Date:  2014-09       Impact factor: 2.931

6.  Parathyroidectomy decreases systolic and diastolic blood pressure in hypertensive patients with primary hyperparathyroidism.

Authors:  Aliya Heyliger; Vin Tangpricha; Collin Weber; Jyotirmay Sharma
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

7.  Endothelial function and arterial stiffness in uncomplicated type 1 diabetes and healthy controls and the impact of insulin on these parameters during an euglycemic clamp.

Authors:  Birgit Wilhelm; Matthias M Weber; Hans Peter Kreisselmeier; Matthias Kugler; Claudius Ries; Andreas Pfützner; Peter H Kann; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2007-07

Review 8.  Derangement of glucose metabolism in hyperparathyroidism.

Authors:  M Procopio; G Borretta
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

Review 9.  Cardiovascular aspects of primary hyperparathyroidism.

Authors:  M D Walker; S J Silverberg
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

Review 10.  Nontraditional manifestations of primary hyperparathyroidism.

Authors:  Marcella Donovan Walker; Mishaela Rubin; Shonni J Silverberg
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.